Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.38 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.38 |
| ▸ | DNM1L | O00429 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | ILK | Q13418 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31122121 | 0.98 | CHEK1 (0.47) | HTR2BCHEK1CYP2C19ACHECYP2C9 | |
| Formic Acid SCHEMBL31708359 | 0.94 | CHEK1 (0.44) | HTR2BCHEK1CYP2C19ACHECYP2C9 | |
| Phosphoric Acid SCHEMBL31122117 | 0.94 | CHEK1 (0.47) | HTR2BCHEK1CYP2C19ACHECYP2C9 | |
| Succinic Acid SCHEMBL31122141 | 0.92 | CHEK1 (0.43) | HTR2BCHEK1CYP2C19ACHECYP2C9 | |
| Cadaverine Tartrate SCHEMBL31122127 | 0.91 | CHEK1 (0.42) | HTR2BCHEK1CYP2C19ACHECYP2C9 | |
| Cadaverine Tartrate SCHEMBL31122154 | 0.91 | CHEK1 (0.42) | HTR2BCHEK1CYP2C19ACHECYP2C9 | |
| SCHEMBL3952859 | 0.86 | ALDH1A1 (0.54) | CHEK1ACHEALDH1A1HPGDSDNM1L | |
| Citric Acid SCHEMBL31122150 | 0.85 | CHEK1 (0.41) | HTR2BCHEK1CYP2C19ACHECYP2C9 | |
| SCHEMBL31122153 | 0.85 | CHEK1 (0.48) | HTR2BCHEK1CYP2C19ACHECYP2C9 | |
| SCHEMBL31122128 | 0.83 | CHEK1 (0.47) | CHEK1ALDH1A1HPGDSDNM1LGPR35 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382470-A1 | Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus | RIGEL PHARMACEUTICALS INC (US) | 2024-11-21 | — | — | US | claimed |
| US-20240174679-A1 | HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-05-30 | — | — | US | claimed |
| EP-3331879-A1 | BENZAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2018-06-13 | — | — | EP | claimed |
| WO-2017023941-A1 | BENZAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | claimed |
| EP-2632263-A1 | NOVEL THIAZOLE-CARBOXAMIDE DERIVATIVES AS PDK1 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | claimed |
| WO-2012058174-A1 | NOVEL THIAZOLE-CARBOXAMIDE DERIVATIVES AS PDK1 INHIBITORS | SCHERING CORPORATION (US) | 2012-05-03 | — | — | WO | claimed |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4536664-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BeiGene, Ltd. (KY) | 2025-04-16 | — | — | EP | disclosed |
| CN-119403805-A | Degradation of IRAK4 by conjugation of IRAK4 inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-118510771-A | IRAK inhibitors for the treatment of conditions associated with cytokine release associated with respiratory viral infection | 里格尔药品股份有限公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-4308115-A1 | HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Merck Sharp & Dohme LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023237049-A1 | DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023089074-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR A SYSTEMIC TREATMENT OF DISEASES AND CONDITIONS | Samsara Therapeutics Inc. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2022187303-A1 | A METHOD FOR TREATING A DISEASE OR CONDITION USING A PYRAZOLE COMPOUND OR FORMULATION THEREOF | RIGEL PHARMACEUTICALS, INC. (US) | 2022-09-09 | — | — | WO | disclosed |
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| CN-114364674-A | Pyrazole compounds, formulations thereof, and methods of using the compounds and/or formulations | 里格尔药品股份有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3331879-A1 | BENZAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017023941-A1 | BENZAZOLE COMPOUNDS AND METHODS FOR MAKING AND USING THE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| EP-2632462-A1 | NOVEL HETEROARYL-CARBOXAMIDE DERIVATIVES AS PDK1 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058176-A1 | NOVEL HETEROARYL-CARBOXAMIDE DERIVATIVES AS PDK1 INHIBITORS | SCHERING CORPORATION (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174679-A1 | HETEROAROYL AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, CLK2, BRSK2 | HTR2B 1545/4885CHEK1 303/4885CYP2C19 2425/4885 |
| US-11370808-B2 | Pyrazole compounds and methods for making and using the compounds | IRAK3, IRAK1, IRAK2 | HTR2B 4109/4885CHEK1 372/4885CYP2C19 3231/4885 |
| US-20250326778-A1 | PYRAZOLE COMPOUNDS AND METHOD FOR MAKING AND USING THE COMPOUNDS | IRAK3, IRAK1, IRAK2 | HTR2B 4061/4885CHEK1 414/4885CYP2C19 3083/4885 |
| US-20240382470-A1 | Irak Inhibitor for Treating Cytokine Release-Related Conditions Associated With Infection by a Respiratory Virus | IRAK1, IRAK4, IRAK2 | HTR2B 1804/4885CHEK1 1571/4885CYP2C19 403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.